U.S. Markets close in 2 hrs.

Omeros' Omidria brand name for OMS302 accepted by FDA

Omeros' proposed brand name for OMS302, Omidria, the company's proprietary product in development for use in intraoperative lens replacement surgery, has been accepted by the FDA. The FDA's acceptance of the proprietary brand name is subject to the agency's final determination prior to any approval of the product's NDA and market launch, expected in 2014. The brand name Omidria was also submitted to the European Medicines Agency, with a decision anticipated later this year.